Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22358408 | 0.86 | KHK (0.44) | HTR1AHTR1BHTR1FHDAC4MAPK14 | |
| SCHEMBL22358418 | 0.85 | KDM4E (0.57) | NAMPTKDM4EPKM | |
| SCHEMBL21611280 | 0.76 | SMN1; SMN2 (0.55) | KDM4E | |
| SCHEMBL20116305 | 0.73 | USP7 (0.41) | KDM4E | |
| SCHEMBL20676536 | 0.73 | PIK3CD (0.37) | HTR1AHTR1BHTR1F | |
| SCHEMBL29491524 | 0.72 | KHK (0.43) | HTR1AHTR1BHTR1FKDM4E | |
| SCHEMBL24339264 | 0.71 | HTR1A (0.43) | HTR1AHTR1BHTR1FKDM4E | |
| SCHEMBL30174436 | 0.71 | HTR1A (0.43) | HTR1AHTR1BHTR1FKDM4E | |
| SCHEMBL22358112 | 0.71 | HDAC4 (0.54) | HDAC4 | |
| SCHEMBL26997918 | 0.70 | IRAK4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NAMPT 473/4885HTR1A 1530/4885HTR1B 1047/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NAMPT 473/4885HTR1A 1530/4885HTR1B 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.